BetaGlue Therapeutics and its shareholders are proud to collaborate with Fondazione Policlinico Universitario Agostino Gemelli in the fight against cancer. Our clinical study in locally advanced pancreatic cancer is on-going. Learn more with this video.
LSI Europe Summit
September 28 – October 2, 2026 | Grand Hyatt Barcelona, Spain
Register interest: info@betaglue.com
CIRSE Annual Congress
September 5-9, 2026 | Copenhagen,
Denmark
Register interest: info@betaglue.com
European Society for Medical Oncology
July 1-4, 2026 | ICM, Munich,
Germany
Register interest: info@betaglue.com
American Society of Clinical Oncology
May 29-June 2, 2026 | McCormick Place, Chicago (IL) – USA & Online
Register interest: info@betaglue.com
Annual Scientific Meeting
11-15 April, 2026 | Metro Toronto Convention Centre – Toronto (ON), Canada
Register interest: info@betaglue.com
LSI USA Summit
March 16-20, 2026 | Monarch Beach, Dana Point,
(CA) – USA
Register interest: info@betaglue.com
World Congress of Interventional Oncology
January 26-27, 2026 | Rome
Register interest: info@betaglue.com
Advancements in the fight against cancer
January 15-17, 2026 | Miami (FL), USA
Register interest: info@betaglue.com
44th Annual J.P. Morgan
January 12-15, 2026 | San Francisco, California
Register interest: info@betaglue.com
Milan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today…
Read moreMilan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid…
Read moreMilan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®,…
Read more
